WithdrawnNot Applicable

Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Diffuse Lesions in the Brain

Stopped: No participants enrolled

Mexico0Started 2011-05

Plain-language summary

The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with diffuse brain lesions and clinical outcomes.

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males and Females between Age 18 and 80 years. * Patient with current diagnosis of Diffuse Brain Lesions with cognitive and/or functional impairment * MRI not showing gross atrophy or any other pathology of brain. * Up to date on all age and gender appropriate cancer screening per American Cancer Society Exclusion Criteria: * Contraindication for MRI * General medical contraindications for minor surgery or angiography * Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study * Life expectancy \< 6 months due to concomitant illnesses. * Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study. * Active infectious disease. Patients known to have tested positive will have an expert consulted as to patient eligibility based on the patient's infectious status * Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results * Patients on chronic immunosuppressive transplant therapy * Systolic blood pressure (supine) ≤90 mmHg; * Resting heart rate \> 100 bpm; * Active clinical infection within one week of enrollment. * Known drug or alcohol dependence or any other factors which will interfere with the study conduct or …

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Improvement in standardized Gross Motor Function Measure evaluation compared to baseline

Timeframe: 3 months

Number of participants with adverse events

Timeframe: up to 6 months

Improved cognitive function as measured by the mini mental state exam

Timeframe: 3 months

Improvement in standardized Gross Motor Function Measure evaluation compared to baseline

Timeframe: 6 months

Improved cognitive function as measured by the mini mental state exam compared to baseline

Timeframe: 6 months

Reduced depressive symptoms measured by the Beck Depression Inventory compared to baseline

Timeframe: 3 months

Reduced depressive symptoms measured by the Beck Depression Inventory compared to baseline

Timeframe: 6 months

Trial details

NCT IDNCT01453777

SponsorAgeless Regenerative Institute

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2014-12

View on ClinicalTrials.gov More Brain Lesion (General) trials

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Improvement in standardized Gross Motor Function Measure evaluation compared to baseline

Timeframe: 3 months

Number of participants with adverse events

Timeframe: up to 6 months

Improved cognitive function as measured by the mini mental state exam

Timeframe: 3 months

Improvement in standardized Gross Motor Function Measure evaluation compared to baseline

Timeframe: 6 months

Improved cognitive function as measured by the mini mental state exam compared to baseline

Timeframe: 6 months

Reduced depressive symptoms measured by the Beck Depression Inventory compared to baseline

Timeframe: 3 months

Reduced depressive symptoms measured by the Beck Depression Inventory compared to baseline

Timeframe: 6 months